CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS

摘要

The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.

主权项

1. A method of treating a patient for a disease, disorder, or condition associated with NGF induced activation of a TrkA receptor, comprising:
administering to a patient in need of said treating, a crystalline polymorph Form A of Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, with the following structure: characterized by having x-ray powder diffraction pattern peak positions at degree two-theta of 10.0±0.3, 20.1±0.3, and 23.6±0.3, wherein said disease, disorder or condition is selected from the group consisting of: restenosis, atherosclerosis, psoriasis, thrombosis, skin disease, inflammation, inflammation related disease, and conditions associated with dysmyelination or demyelination.